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ABSTRACT
The CCAAT-binding protein NF-Y is involved in the
regulation of a variety of eukaryotic genes and is
formed in higher eukaryotes by three subunits NF-YA/
B/C. We have characterized NF-Y of the trematode
parasite Schistosoma mansoni and studied the structure
and the function of the SMNF-YA subunit. In this work,
we present the cloning and sequence analysis of the B
subunit of the parasite factor. SMNF-YB contains the
conserved HAP-3 homology domain but the remaining
part of the protein was found to be highly divergent from
all other species. We demonstrated by transfections of
GAL4 fusion constructs, that mouse NF-YB does not
contain activation domains while the C-terminal part of
SMNF-YB has transcriptional activation potential. On
the other hand, the N-terminal parts of SMNF-YA and
mouse NF-YA were shown to mediate transactivation;
the integrity of a large 160 amino acid glutamine-rich
domain of NF-YA was required for this function and an
adjacent serine- and threonine-rich domain was
necessary for full activity in HepG2, but redundant in
other cell types. Transactivation domains identified in
SMNF-YB are also rich in serine and threonine residues.
Our results indicate that serine/threonine-rich
sequences from helminth parasites potentiate trans-
cription and that such structures have diverged during
evolution within the same transcription factor.
INTRODUCTION
NF-Y (also called CBF, CP1) is a ubiquitous heteromeric
complex that binds to the widespread CCAAT sequence present
in the promoters and enhancers of a variety of eukaryotic genes
(1,2). NF-Y has an absolute requirement for the CCAAT box as
well as a strong preference for specific flanking sequences (3,4).
NF-Y from higher eukaryotes is formed by three subunits,
NF-YA, NF-YB and NF-YC (5,6). All subunits are required for
DNA binding (6). Saccharomyces cerevisiae also has a CCAAT-
binding activity displayed by the HAP-2/3/4/5 complex that is
specifically required to activate transcription when cells are
grown on a non fermentable carbon source (7–9). NF-YA/B/C
subunits present a significant degree of identity with yeast
HAP-2, HAP-3 and HAP-5 factors, respectively, in conserved
regions called the HAP-2/3/5 homology domains (6,7,10). The
yeast HAP-4 protein is not needed for DNA-binding but contains
an acidic domain that is essential to promote transactivation when
associated with the HAP-2/3/5 complex (11).
NF-YB and NF-YC form a dimer which in turn interacts with
NF-YA allowing the whole complex to bind DNA (6). Interestingly,
the conserved HAP-3/5 homology domains within NF-YB–NF-YC
have sequence similarities to the histone fold motifs (HFM) of the
H2B and H2A histones respectively, and to the archaebacterial
histone-like protein Hmf-2 (12). A previous mutational analysis
of NF-YA indicated that the HAP-2 homology domain contains
a segment for interaction with other NF-Y subunits and a domain
necessary for DNA binding (11,13,14). NF-YA does not present
similarity to known interfaces and motifs and therefore constitutes
an unusual heteromeric DNA-binding factor.
Transcriptional activation functions of transacting factors
generally lie on domains localized outside of the DNA-binding
regions. Several transcription factors are classified according to
their motifs capable of mediating transcriptional activation such
as acidic, glutamine-rich and proline-rich (15,16). In higher
eukaryotes, NF-Y transcriptional activation has been shown to be
essentially displayed by the NF-YA and NF-YC subunits. NF-YA
transactivation domains were predominantly localized in the
N-terminal region of the subunit which is highly rich in glutamine
(35%) and flanked on its C-terminal side by a stretch of
serine/threonine residues. On the other hand, the NF-YC
transactivation activity is contained in the C-terminal part of the
protein, which is very hydrophobic and also highly rich in
glutamine residues (17,18).
We have already characterized the NF-YA subunit of the
human blood fluke Schistosoma mansoni (SMNF-YA). We have
shown that the HAP-2 homology domain is highly conserved in
SMNF-YA, that is able to associate with the mammalian
NF-YB/C subunits to form a complex with affinity to Y boxes
derived from the 5′ flanking region of the Sm28GST parasite
gene (19,20). These results are in line with the functionality of the
schistosome HAP-2 homology domain and the existence of
NF-YB/C subunits in this parasite.
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In this paper, we present and analyse the complete sequence of the
B subunit from the SMNF-Y complex (SMNF-YB). As expected,
SMNF-YB shows a high degree of conservation in the HAP-3
homology domain, containing the HFM and the TATA binding
protein (TBP)-binding domain (21). By contrast, the remaining part
of the protein is completely divergent from the mammalian and yeast
counterparts. No glutamine stretches are found in the SMNF-YB
N-terminus, while a large C-terminal region is rich in serine and
threonine. Interestingly, the parasite NF-YB, unlike its eukaryotic
counterpart, is herein shown to mediate transactivation via its
serine/threonine-rich domain, suggesting the ability of such a
structure to potentiate transactivation in helminth parasites.
MATERIALS AND METHODS
Cloning of the S.mansoni NF-YB subunit
The following degenerated oligonucleotides were designed
following comparison of the HAP-3 homology region from yeast
and mammalian proteins: 5′-AA(AG)GA(TC)GCAA(AG)-
GA(AG)-3′ and 5′-AT(AG)TC(CT)TCICC(GA)TTIAT-3′. These
oligonucleotides were used in a touchdown PCR (22) on first
strand adult S.mansoni cDNA. The touchdown PCR was
performed using decreasing annealing temperatures as follows:
45C for 5 cycles, 40C for 5 cycles and 37C for the last
25 cycles. Amplification products were cloned in the pCRII
plasmid (InVitrogen), sequenced and used as probes for screening
of a λgt10 adult S.mansoni cDNA library.
NF-YA and NF-YB transactivation regions—DBD Gal
constructs
Different oligonucleotide pairs were synthesized in order to generate
an SMNF-YA segment coding from the M2 to the G171 residue
positions (SmYA10: 5′-AAAGGATCCATGGACGGTTATATAC-
ACGCT-3′; SmYA12: 5′-AAAACTAGTGCCGCCAGGAGTA-
AGACCAGG-3′) and the SMNF-YB C-terminal region from the
S119 to the S242 residue position (SmYB3: 5′-AAAGGATCCTC-
TTCATTCATTGATGAATCA-3′; SmYB2: 5′-AAAGCGGCCG-
CAGAAACTGAATCCGTCGATTC-3′). We also generated frag-
ments corresponding to halves of this SMNF-YB C-terminal region
from the S119 to the M198 residue (SmYB3; SmYB4: 5′-AAAGC-
GGCCGCCATTCCAGCATTTGCTACTTT-3′) and from the
K192 to the S242 residue (SmY4: 5′-AAAGGATCCAAAGTAGC-
AAATGCAGGAATG-3′; SmYB2). All the oligonucleotides con-
tain adequate restriction sites to allow further cloning steps. The
amplification products were initially cloned in the pCRII plasmid
and sequenced. The corresponding fragments were purified after
digestion with restriction enzymes and ligated into the pGAP424
plasmid in frame with the DBD Gal domain (23).
All mouse NF-YA and NF-YB GAL4 fusions, and mutants
thereof, were generated by PCR using oligonucleotides containing
ClaI and BglII (for YA), or BamHI (for YB) sites and cloned into
the corresponding sites in the polylinker of the GAL4-1-147
vector described in 24. All clones were checked by sequencing.
The positive control GAL4 vector and the reporter MX2-CAT
and M2TATA-CAT vectors were also described in 24.
Cell transfections
Cells were co-transfected with the pGAP424 constructs and the
pG5TATALuc (25) containing the luciferase reporter gene under
the control of five GAL4-specific target sequences. The
pCMV-βGal plasmid was also used for control of transfection
efficiency (26). All the plasmids used in these experiments were
purified by centrifugation using cesium chloride gradients as
described (27). HeLa cells were maintained in RPMI 1640
(Gibco) medium supplemented with 10% fetal calf serum.
HepG2 NIH3T3 and Cos-1 cells were maintained in Dulbecco’s
minimum essential medium, supplemented with 10% fetal calf
serum. Cells were transfected by using polyethyleneimine
(ExGen ET250, Euromedex) as indicated by the suppliers. Cells
were recovered 18–24 h after transfection, washed in PBS (150 mM
NaCl, 10 mM sodium phosphate, pH 7.4) and resuspended in the
reporter assay reagent (Promega). Luciferase activity was
measured as described (28) using 25 mM ATP and 150 mM
D-luciferin substrate in a 180 µl final volume. Light production
was quantified in a Nucleotimetre 107 (Interbio). β-galactosidase
activity was measured in 60 mM Na2HPO4, 40 mM NaH2PO4,
1 mM MgCl2, 50 mM 2-mercaptoethanol and 0.66 mg/ml O-nitro-
phenyl β-D galactopyranoside (ONPG) in a 300 ml final volume
(29). After 30 min of incubation at 37C, the reaction was stopped
by adding 700 µl of 1 M Na2CO3 and the A420nm was measured.
Luciferase activity values were corrected using the β-galactosidase
activity expressed in each sample as a reference (26).
For transfections with mouse NF-YA and NF-YB mutants, 2 µg
of CAT vectors and 5 µg of activating plasmids were used together
with Nβ-Gal internal vector (a gift of Dr S.Weisz, University of
Naples, Italy). HeLa, NIH3T3 and HepG2 were transfected with a
standard calcium–phosphate technique, while M12 cells were
transfected by electroporation. Briefly, exponentially growing cells
(2.107) were centrifuged and resuspended in 400 µl of PBS. DNA
was added, keeping a 25 µg final amount of transfected DNA by
adding Bluescript plasmid DNA. Cells and DNA were kept on ice
for 10 min and electroporated at 960 µF, 280 V with a Bio-Rad
apparatus. To the transfected cells, 10 ml of complete medium
were immediately added. After 48 h, cells were centrifuged and
extracts prepared by repeated cycles of freezing–thawing,
normalized with a β-Gal assay and tested in a standard CAT assay.
For western blots, a normalized amount of whole cell extracts
(∼100 µg) was loaded on a 12% SDS gel, blotted and assayed with
an anti-GAL4 monoclonal antibody (a kind gift of Dr Y.Lutz,
IGBMC, Strasbourg, France).
RESULTS AND DISCUSSION
The DNA-binding and subunit interaction (HAP-3) domain of
NF-YB appeared to be highly conserved at the primary sequence
level. Based on this observation, we considered the possibility of
isolating the S.mansoni NF-YB counterpart by a PCR-based
strategy using degenerate oligonucleotides similar to the flanking
regions of the conserved HAP-3 homology domain. Amplification
was performed on adult S.mansoni cDNA that generated a major
product of 130 bp. The sequence of the PCR product was
determined, showing a high identity with the HAP-3 homology
domain from yeast and mammalian factors. Further screening of
an adult S.mansoni cDNA library, using the 130 bp DNA
fragment as a probe, led us to the isolation of several clones
containing a unique inserted sequence of 1547 bp with an open
reading frame encoding a polypeptide of 242 amino acids
homologous to the yeast HAP-3 and human NF-YB (CBF-A)
proteins, named SMNF-YB.
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Figure 1. Sequence alignment of NF-YB subunits. Amino acid sequence of
SMNF-YB (Sm) was compared to human (H) and S.cerevisiae (Sc) proteins
(37). Dashes indicate the residues shared between S.mansoni and human and/or
yeast proteins. The HAP-3 homology domain is boxed. The HFM is underlined
and the TBP-binding domain is in italics. Stars indicate the positions of β-sheet
structures in SMNF-YB predicted by the Garnier–Robson algorithm. The
nucleotide sequence of SMNF-YB has been deposited to DDBJ/EMBL/GenBank
under the accession no. AF037602.
As shown in Figure 1, a region highly similar to human and
yeast proteins (80 and 61.5% identity, respectively) was observed
between the P30 and the L104 residues of the schistosome
protein. This region contained the HFM already described in the
HAP-3 homology domain of the human and yeast factors (12) and
shown to be dependent on strict structural constraints for
function. A conserved domain has also been described within the
HAP-3 homology domain as a short segment adjacent to HFM
and necessary for TBP-binding (21). A similar TBP-binding
domain was also found at the same position (between N99 and
R105 residues) in the SMNF-YB sequence.
The N-terminal part of SMNF-YB was found to be shorter than
that of other factors and very different at the protein sequence level.
The remaining part of the protein was also completely different from
that of already described NF-YBs. The SMNF-YB C-terminal
region was larger than that of yeast and mammalian proteins and
does not show identity with any other sequences. In particular,
neither glutamine nor proline stretches characteristic for transactiva-
tion domains in mammalian transcription factors, are present in the
S.mansoni NF-YB subunit. Interestingly, the C-terminal portion of
SMNF-YB showed a high content of serine/threonine (30.3%) and
proline (8.2%), and was also rich in valine (9.8%) residues. Analysis
of this region using the Garnier–Robson algorithm, revealed that it
may adopt a structure formed by six β-sheets, each composed of
13–23 residues and homogeneously distributed from the end of the
HAP-3 homology region to the C-terminus of the protein. The same
algorithm analysis was not able to predict any similar structure in
yeast or mammalian protein sequences.
In mammals, NF-Y-dependent activation processes are mainly
mediated by NF-YA and NF-YC subunits (17,30) while in yeast,
CCAAT-dependent transactivation activity has been attributed to
the HAP-4 component (11). The SMNF-YA subunit does show
the typical glutamine-rich transactivation domain found in the
N-terminal part of NF-YA proteins from higher eukaryotes but
contains also an elevated proportion of serine/threonine residue
in its N-terminal region (19). A small group of transcription
activators contain activation domains that have been already
characterized as serine- and threonine-rich. These include the
C-terminal activation domain of Oct-2 (31,32), which also
possesses a high proline content, and the enhancer binding proteins
ITF-1, ITF-2 and TFE3 (for review see 33). Moreover, the concept
that activation domains often harbour multiple small subdomains is
now well established. This idea first proposed for the yeast activators
GAL4 and GCN4 has since been demonstrated for a large number
of activators from different origins (for review see 34).
Taking into account the serine/threonine contents of both the
C-terminal region of SMNF-YB and the N-terminal part of
SMNF-YA, as well as the modular structure predicted for the
SMNF-YB region, we decided to study the transactivation
potential of these two factors in order to provide new information
about transactivation processes in helminths. Proteins were fused
to the DNA-binding domain of the GAL4 yeast factor, which
conserves the ability to bind the GAL4 DNA target sequences, but
lacks activation activity. Four fusion proteins were prepared, as
shown in Figure 2A and B. Two of these proteins contained the
complete N-terminal sequence of SMNF-YA and the complete
C-terminal sequence of SMNF-YB, respectively. The other
fusion proteins contained halves of the C-terminal region of
SMNF-YB. These plasmids were co-transfected with a construct
containing the luciferase reporter gene under the control of five
tandem GAL4 specific target sequences. The results presented in
Figure 2C demonstrate that SMNF-YA and SMNF-YB chimeric
proteins exhibited transactivation activity. In the three mam-
malian cell lines tested, the luciferase activity was higher than that
obtained with the control DBD Gal plasmid. Interestingly, for two
cell lines, the maximal luciferase activity was detected with the
construct containing the whole C-terminal region of SMNF-YB.
In addition, the two fusion proteins containing each half of the
SMNF-YB activation region mediate nearly half the activity
obtained with the whole C-terminal segment of SMNF-YB.
These observations demonstrate the potential of SMNF-YB for
transactivation and support the concept of a modular structure of
the transactivation domain.
In parallel, we subjected mouse NF-YA and NF-YB to the same
type of analysis. Figure 3A shows that, of the several mutants
used, only YA5, YA6, YA11 and YA12 were active on the
M2TATA-CAT reporter plasmid, both in HepG2 and in M12 B
lymphocytes. Mutants lacking the N-terminal glutamine-rich
were all inactive, as were constructs in which the glutamine-rich
domain was split (YA14, YA15 and YA16). Surprisingly,
constructs containing both the activation domain and the HAP2
conserved domain were also devoid of any activating potential
(YA1, YA4, YA10 and YA13). Moreover, mutants containing the
serine- and threonine-rich domain showed distinctively higher
activities in HepG2, while mutants YA6 and YA12, lacking this
part of NF-YA, were higher in M12 (Fig. 3A) as well as in
NIH3T3 and HeLa cells (data not shown), suggesting that
cell-type preference plays a role in activation potential by this
domain. To rule out the possibility that these results were due to
poor expression of some of the mutants, we checked expression
of all mutants in transfections by performing western blot analysis
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Figure 2. Analysis of SMNF-YA and SMNF-YB activation domains. (A) Schematic representation of SMNF-YA and SMNF-YB proteins showing the conserved HAP
regions and the putative transactivation regions. (B) Plasmid contructs containing the SMNF-YA and SMNF-YB activation regions fused to the DBDGal DNA-binding
domain from GAL4. (C) Analysis of the transactivation activity of the plasmid contructs in three different cell lines. Typical results from four experiments are presented.
with an anti-GAL4 antibody: Figure 3B shows that mutants
negative in transcription were present at equal levels compared to
the functioning fusion proteins.
The same type of experiment was tried with mouse NF-YB–
GAL4DBD fusions (Fig. 4): in this case, neither the wt NF-YB,
nor any of the mutants showed any detectable degree of activation
on the M2TATA-CAT vector. To further prove that mouse NF-YB
subunit is truly devoid of any activating potential in this assay and
rule out that more than two GAL4 sites are required for NF-YB
proteins, we tried the more sensitive cis-vector containing the TK
promoter in front of two GAL4 sites. As shown in Figure 4, this
vector was efficiently activated by the positive GAL4 control, but
not by any of the NF-YB constructs: if anything, a small but
reproducible degree of repression was observed. We also
transfected NIH3T3 cells in parallel with SMNF-YB, mouse
NF-YB and YA6, with the 5× GAL4 sites-containing vector used
before: the results shown in Table 1 indicate that unlike
SMNF-YB, mouse NF-YB does not activate. This experiment
also allowed us to quantify the YA6 potential as being of similar
magnitude with respect to the SMNF-YA and SMNF-YB. In
these experiments, the expression efficiency of all mutants was
controlled by western blot analysis, as described for NF-YA
constructs (data not shown). Moreover, the mouse GAL4-NF-YB
constructs do activate, provided that the two other subunits are
cotransfected (A.di Silvio and R.Mantovani, in preparation). The
conclusion of this set of experiments is that mouse and
schistosome NF-YA are both able to activate transcription, while
only the helminth NF-YB harbours such potential.
Table 1. Comparative analysis of schistosome and mouse NF-YB
transcriptional potential
Plasmid Luciferase activity (fold activation)
GAL4Poly 1
GAPYB (S.mansoni) 10.4
GALYB (mouse) 1.6
GALYA (mouse) 11.1
Luciferase activity was measured in NIH3T3 cells co-transfected with NF-Y
constructs and pG5TATALuc plasmid.
NF-Y represents an ideal system to follow conservation/
divergence of transcriptional activation domains. Unlike many
general transcription factors (such as TBP, TFIIB, TFIIA, etc.)
which are highly conserved, but do not possess a distinct
transcription activating domain, and unlike many DNA-binding
factors, whose conservation in different phyla is much lower and
restricted to the DNA-binding domain, NF-Y shows among the
highest degree of conservation (67–73% identity, 85–90%
similarity) in the subunit association and DNA-contacting parts,
but also in recognizable activating domains. At this time, little is
known about transcription factors in helminth parasites. Besides
the A subunit of the SMNF-Y complex, a limited number of
Schistosoma transcription factors have been described, that
include the Heat Shock Factor (HSF) (35) and several nuclear
receptors considered as transcriptional regulators (36). In all cases,
a relatively high conservation of sequences involved in the binding
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Figure 3. Transcriptional activation of mouse NF-YA. (A) The scheme depicts the wt short (YA1) and long (YA13) forms of NF-YA proteins fused to the DNA-binding
domain of GAL 4. YA2 (amino acids 161–346), YA3 (amino acids 262–346), YA4 (amino acids 1–317), YA5 (amino acids 1–261), YA6 (amino acids 1–160), YA8
(amino acids 161–317), YA9 (amino acids 262–317). YA10, YA11, YA12 are equivalent to YA4, YA5, YA6, except that they contain the 28 amino acids of the optional
exon B (46). YA14 (amino acids 1–70, short form), YA15 (amino acids 1–70 long form), YA16 (amino acids 71–160). The reporter CAT vector M2TATA-CAT contains
two GAL4-binding 17mers in front of the AdML TATA box (24). (B) Western blot analysis of extracts derived from HeLa cells transfected with the indicated YA
mutants using an anti-GAL4 monoclonal antibody.
BA
Figure 4 .Transcriptional potential of mouse NF-YB. GAL4–NF-YB constructs were made essentially as described for NF-YA in Figure 3. YB-1 (amino acids 1–161),
YB2 (amino acids 1–50), YB4 (amino acids 51–140), YB6 (amino acids 141–207). The N- and C-terminal domains of NF-YB are indicated by dotted boxes, while
a grey box indicates the central conserved domain of NF-YB. Results of transfection of HeLa cells with M2TATA-CAT (left panel) or MX2-CAT (containing a tandem
of GAL4-binding 17mers fused to the TK promoter) are presented.
to specific DNA targets was observed between schistosomes and
higher eukaryotes. However, no significant identity was found when
other regions, particularly activation domains of mammalian
factors, were compared to their Schistosoma counterparts.
The NF-YA N-terminal domains of mammals, sea urchin,
S.mansoni and Aspergillus nidulans contain clearly recognizable
glutamine-rich domains (19,37, R.Mantovani, unpublished).
Similar in overall amino acid composition, hydrophobics pre-
dominate as well as glutamines, they are largely different in the
primary structure. Many factors of different phylogenetic origins
have been shown to activate transcription by their acidic- and/or
proline-rich transactivation domains in the budding yeast
(38–40). The S.cerevisiae acidic transcription factor GAL4 also
activates transcription in mammals as well as in plants, suggest-
ing a conserved and interchangeable mechanism of acidic
transactivation factors throughout evolution (41,42). In contrast,
glutamine-rich domains, such as those found in the human SP1
factor, failed to potentiate activation of transcription in S.cerevi-
siae (43), while they were functional in Schizosaccharomyces
pombe (44). Results indicating that glutamine-rich sequences
have different functions in human, S.pombe and S.cerevisiae
could mean that such domains need additional transcription
cofactors which are present in mammals and absent, or playing
distinct functions, in S.cerevisiae. In keeping with this observa-
tion, a recent paper reported binding of NF-YA–NF-YC Q-rich
activation domains to dTAFII110 (45), one of the few TBP-asso-
ciated factors for which no S.cerevisiae counterpart has been
found so far. In S.cerevisiae, a fourth subunit, HAP-4, containing
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a powerful highly acidic domain is required to activate the
HAP-2/3/5 complex: this subunit is apparently absent in other
phyla, where the activating information has been incorporated
within the core subunits within complex, perhaps modulable
domains. In NF-YA, a serine- and threonine-rich segment was
described as being essential for full transactivation in concert with
the glutamine-rich region in an in vitro system (17). The data of
transfections in different cell lines presented here support the idea
that this domain is necessary for full activation in some but not all
cell lines, thus suggesting that activation is influenced by the
cell-type context, probably reflecting the existence, or abundance,
of intermediate cell-specific cofactors capable of mediating
activation in a given cell type. It is worth noting that mouse NF-YA
activation emerges only in GAL4 constructs devoid of the HAP-2
homology domain: this could be explained by supposing that such
fusion proteins are complexed by the endogenous NF-YB–NF-YC
dimer that can then bind the plethora of CCAAT-box targets in the
genome, or that additional nuclear factors exist that mask the
activation domain. Further experiments are needed to discriminate
between these possibilities. Our observations suggest that NF-Y
protein identity is restricted to the HAP-2/3/5 homology domains,
the latter two containing putative histone fold domains and favour
of a complex evolution of the structure/function of NF-Y factors
as well as of other transcription factors.
Our study, performed in mammalian cells, represents the first
indication that activation domains of a Schistosoma transcription
factor, as divergent from human as it is from yeast, efficiently
operates in a mammalian context. The results presented here also
show, for the first time, the existence of a functional activation
domain in the B subunit of an NF-Y complex. We found that,
unlike NF-YA and NF-YC that mediate transactivation via their
glutamine-rich domains, the mouse NF-YB subunit is completely
unable to potentiate transcription in higher eukaryotes. Our
experiments suggest a model whereby transactivation by NF-Y in
helminth parasites could be mediated by the A and B subunits via
glutamine- and serine/threonine-rich domains, with the latter
being slightly more efficient. This observation could also signify
the preference for serine/threonine-rich conformations as activators
for the schistosome RNA PolII, depending on the context of the
parasite promoters and the position of DNA-binding sites that
govern responsiveness to different regulatory signals. The fact
that the C-terminal region of SMNF-YA also contains serine and
threonine residues in addition to glutamines, when compared
with the mammalian NF-YA (19), is in line with this hypothesis.
Further cloning and analysis of the third SMNF-YC subunit will
certainly shed more light on the evolution of transcription
activating function of this conserved transcription factor.
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